Equity Field Notes from temporal sources

[DanWebzster]

XBIT is primarily focused on the development of True Human Antibodies for conditions with high unmet need.

The XBIT program that seems to capture the most interest is an antibody product for managing strokes. This could be a large opty because there is presently no treatment for brain damage caused by reperfusion of stroke patients.

Q2/20, XBIT discovered a new class of antibodys from a human donor. They sold a similar technology to JnJ, but retained the right to develop novel True Human Antibodies unrelated to Dermatological conditions.

True Human Antibodies are antibodies derived from humans who possess rare immunity to specific conditions.

XBIT has 3 Covid-related programs:

* Convalescent plasma collection
* A test that identifies antibodies that are useful in treating
life-threatening cases of Covid
* Development of a True Human Antibody against Covid.


XBIT lead program is in PhII against Staph. Aureus Bacterium

XBIT offers both manufacturing and clinical trial services to other Pharmas. They entered this business as part of the sale of their Derm program to JnJ.

Q1/20 Cash was 241M

CEO/founder owns 17.6% of the company.